The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma

NCT05839275 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

High-Risk Localized Soft Tissue Sarcoma

Interventions

DRUG: Surufatinib
DRUG: Sintilimab
RADIATION: Radiotherapy

Sponsor

Fudan University